Report Detail

Request for Sample of this report

Pharma & Healthcare Global Omalizumab Biosimilars Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4708383
    • |
  • 17 June, 2026
    • |
  • Global
    • |
  • 111 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Omalizumab Biosimilars market size was valued at US$ 298 million in 2025 and is forecast to a readjusted size of US$ 606 million by 2032 with a CAGR of 11.0% during review period.
In 2025, global Omalizumab Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
This report is a detailed and comprehensive analysis for global Omalizumab Biosimilars market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Omalizumab Biosimilars market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Omalizumab Biosimilars market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Omalizumab Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Omalizumab Biosimilars market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Omalizumab Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Omalizumab Biosimilars market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Omalizumab Biosimilars market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
150 mg/mL
75 mg/0.5 mL
Market segment by Age
For Adults
For Teenagers
For Children
Market segment by Frequency
Every 2 Weeks
Every 4 Weeks
Individualized Dosing Regimen
Market segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Major players covered
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Omalizumab Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Omalizumab Biosimilars, with price, sales quantity, revenue, and global market share of Omalizumab Biosimilars from 2021 to 2026.
Chapter 3, the Omalizumab Biosimilars competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Omalizumab Biosimilars breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Omalizumab Biosimilars market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Omalizumab Biosimilars.
Chapter 14 and 15, to describe Omalizumab Biosimilars sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Omalizumab Biosimilars Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 150 mg/mL
    • 1.3.3 75 mg/0.5 mL
  • 1.4 Market Analysis by Age
    • 1.4.1 Overview: Global Omalizumab Biosimilars Consumption Value by Age: 2021 Versus 2025 Versus 2032
    • 1.4.2 For Adults
    • 1.4.3 For Teenagers
    • 1.4.4 For Children
  • 1.5 Market Analysis by Frequency
    • 1.5.1 Overview: Global Omalizumab Biosimilars Consumption Value by Frequency: 2021 Versus 2025 Versus 2032
    • 1.5.2 Every 2 Weeks
    • 1.5.3 Every 4 Weeks
    • 1.5.4 Individualized Dosing Regimen
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Omalizumab Biosimilars Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Persistent Asthma
    • 1.6.3 Nasal Polyps
    • 1.6.4 Chronic Idiopathic Urticaria
  • 1.7 Global Omalizumab Biosimilars Market Size & Forecast
    • 1.7.1 Global Omalizumab Biosimilars Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Omalizumab Biosimilars Sales Quantity (2021-2032)
    • 1.7.3 Global Omalizumab Biosimilars Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Omalizumab Biosimilars Product and Services
    • 2.1.4 Roche Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis Omalizumab Biosimilars Product and Services
    • 2.2.4 Novartis Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments/Updates
  • 2.3 Glenmark Pharmaceuticals
    • 2.3.1 Glenmark Pharmaceuticals Details
    • 2.3.2 Glenmark Pharmaceuticals Major Business
    • 2.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Product and Services
    • 2.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
  • 2.4 Selexis
    • 2.4.1 Selexis Details
    • 2.4.2 Selexis Major Business
    • 2.4.3 Selexis Omalizumab Biosimilars Product and Services
    • 2.4.4 Selexis Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Selexis Recent Developments/Updates
  • 2.5 Generium
    • 2.5.1 Generium Details
    • 2.5.2 Generium Major Business
    • 2.5.3 Generium Omalizumab Biosimilars Product and Services
    • 2.5.4 Generium Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Generium Recent Developments/Updates
  • 2.6 CuraTeQ
    • 2.6.1 CuraTeQ Details
    • 2.6.2 CuraTeQ Major Business
    • 2.6.3 CuraTeQ Omalizumab Biosimilars Product and Services
    • 2.6.4 CuraTeQ Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 CuraTeQ Recent Developments/Updates
  • 2.7 Celltrion Healthcare
    • 2.7.1 Celltrion Healthcare Details
    • 2.7.2 Celltrion Healthcare Major Business
    • 2.7.3 Celltrion Healthcare Omalizumab Biosimilars Product and Services
    • 2.7.4 Celltrion Healthcare Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Celltrion Healthcare Recent Developments/Updates
  • 2.8 Alvotech
    • 2.8.1 Alvotech Details
    • 2.8.2 Alvotech Major Business
    • 2.8.3 Alvotech Omalizumab Biosimilars Product and Services
    • 2.8.4 Alvotech Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Alvotech Recent Developments/Updates
  • 2.9 BiosanaPharma
    • 2.9.1 BiosanaPharma Details
    • 2.9.2 BiosanaPharma Major Business
    • 2.9.3 BiosanaPharma Omalizumab Biosimilars Product and Services
    • 2.9.4 BiosanaPharma Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 BiosanaPharma Recent Developments/Updates
  • 2.10 Mabpharm
    • 2.10.1 Mabpharm Details
    • 2.10.2 Mabpharm Major Business
    • 2.10.3 Mabpharm Omalizumab Biosimilars Product and Services
    • 2.10.4 Mabpharm Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Mabpharm Recent Developments/Updates
  • 2.11 CSPC Pharmaceutical Group
    • 2.11.1 CSPC Pharmaceutical Group Details
    • 2.11.2 CSPC Pharmaceutical Group Major Business
    • 2.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Product and Services
    • 2.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
  • 2.12 Biomabs
    • 2.12.1 Biomabs Details
    • 2.12.2 Biomabs Major Business
    • 2.12.3 Biomabs Omalizumab Biosimilars Product and Services
    • 2.12.4 Biomabs Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Biomabs Recent Developments/Updates
  • 2.13 HisunPharm
    • 2.13.1 HisunPharm Details
    • 2.13.2 HisunPharm Major Business
    • 2.13.3 HisunPharm Omalizumab Biosimilars Product and Services
    • 2.13.4 HisunPharm Omalizumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 HisunPharm Recent Developments/Updates

3 Competitive Environment: Omalizumab Biosimilars by Manufacturer

  • 3.1 Global Omalizumab Biosimilars Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Omalizumab Biosimilars Revenue by Manufacturer (2021-2026)
  • 3.3 Global Omalizumab Biosimilars Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Omalizumab Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Omalizumab Biosimilars Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Omalizumab Biosimilars Manufacturer Market Share in 2025
  • 3.5 Omalizumab Biosimilars Market: Overall Company Footprint Analysis
    • 3.5.1 Omalizumab Biosimilars Market: Region Footprint
    • 3.5.2 Omalizumab Biosimilars Market: Company Product Type Footprint
    • 3.5.3 Omalizumab Biosimilars Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Omalizumab Biosimilars Market Size by Region
    • 4.1.1 Global Omalizumab Biosimilars Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Omalizumab Biosimilars Consumption Value by Region (2021-2032)
    • 4.1.3 Global Omalizumab Biosimilars Average Price by Region (2021-2032)
  • 4.2 North America Omalizumab Biosimilars Consumption Value (2021-2032)
  • 4.3 Europe Omalizumab Biosimilars Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Omalizumab Biosimilars Consumption Value (2021-2032)
  • 4.5 South America Omalizumab Biosimilars Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Omalizumab Biosimilars Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Omalizumab Biosimilars Sales Quantity by Type (2021-2032)
  • 5.2 Global Omalizumab Biosimilars Consumption Value by Type (2021-2032)
  • 5.3 Global Omalizumab Biosimilars Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Omalizumab Biosimilars Sales Quantity by Application (2021-2032)
  • 6.2 Global Omalizumab Biosimilars Consumption Value by Application (2021-2032)
  • 6.3 Global Omalizumab Biosimilars Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Omalizumab Biosimilars Sales Quantity by Type (2021-2032)
  • 7.2 North America Omalizumab Biosimilars Sales Quantity by Application (2021-2032)
  • 7.3 North America Omalizumab Biosimilars Market Size by Country
    • 7.3.1 North America Omalizumab Biosimilars Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Omalizumab Biosimilars Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Omalizumab Biosimilars Sales Quantity by Type (2021-2032)
  • 8.2 Europe Omalizumab Biosimilars Sales Quantity by Application (2021-2032)
  • 8.3 Europe Omalizumab Biosimilars Market Size by Country
    • 8.3.1 Europe Omalizumab Biosimilars Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Omalizumab Biosimilars Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Omalizumab Biosimilars Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Omalizumab Biosimilars Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Omalizumab Biosimilars Market Size by Region
    • 9.3.1 Asia-Pacific Omalizumab Biosimilars Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Omalizumab Biosimilars Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Omalizumab Biosimilars Sales Quantity by Type (2021-2032)
  • 10.2 South America Omalizumab Biosimilars Sales Quantity by Application (2021-2032)
  • 10.3 South America Omalizumab Biosimilars Market Size by Country
    • 10.3.1 South America Omalizumab Biosimilars Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Omalizumab Biosimilars Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Omalizumab Biosimilars Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Omalizumab Biosimilars Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Omalizumab Biosimilars Market Size by Country
    • 11.3.1 Middle East & Africa Omalizumab Biosimilars Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Omalizumab Biosimilars Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Omalizumab Biosimilars Market Drivers
  • 12.2 Omalizumab Biosimilars Market Restraints
  • 12.3 Omalizumab Biosimilars Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Omalizumab Biosimilars and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Omalizumab Biosimilars
  • 13.3 Omalizumab Biosimilars Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Omalizumab Biosimilars Typical Distributors
  • 14.3 Omalizumab Biosimilars Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Omalizumab Biosimilars. Industry analysis & Market Report on Omalizumab Biosimilars is a syndicated market report, published as Global Omalizumab Biosimilars Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Omalizumab Biosimilars market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo